Hetero Biopharma’s 1st commercial launch in Global Markets -launch of Derise (Darbepoetin Alfa) in Cambodia.
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Derise’ (Darbepoetin Alfa) in Phnom Penh, the capital city of Cambodia on 18th May 2017. Cambodia is the 1st market to get approval of Derise (Darbepoetin Alfa) and Rilast (Rituximab) approval is expected shortly. Spearheaded by Mr. A V Jayapala Reddy, AVP & Global Head Biologics Business Development, Dr. Praveen Shetty - AGM, Global Clinical Strategy & Medico Marketing and Mr. Pundari Baba, CEO TELPHA Inc – Hetero’s business partner in Cambodia – the product Derise was launched in the presence of leading nephrologists. Mr. Venkata Ramana, Sr. GM International Marketing and Mr. Ravi -Manager International Marketing, Mr. Madhu, Marketing Head TELPHA INC were also present during the launch meeting.
This event served a great platform to launch Hetero BioPharma and its expertise in the area of Biosimilars. During this launch event, Dr. Praveen Shetty – AGM, Global Clinical Strategy and Medico Marketing made a presentation on ‘Clinical implication of Darbepoetin alfa in CKD Induced Anemia” to the doctors.
Subsequent to the launch, on 19th May 2017, Mr. Murali – Director, International marketing interacted with distributors and shared the overall vision of Hetero for Cambodian market. An exclusive training programme was also organized for the sales force of Cambodia.
On 23rd May 2017, Dr. Praveen Shetty along with our business partner TELPHA, launched Derise to a group of leading oncologists through a continuing medical education (CME) programme on “Clinical implication of Darbepoetin in Chemotherapy induced Anemia”.
We congratulate the entire team of Hetero Biopharma for the successful launch.